1 Min Read
April 19 (Reuters) - Krystal Biotech Inc:
* KRYSTAL BIOTECH’S KB103 RECEIVES ORPHAN MEDICINAL PRODUCT DESIGNATION IN EUROPE FOR DYSTROPHIC EPIDERMOLYSIS BULLOSA Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.